2026 CLL Update: Game Changer Therapies for Oncologists?

In this expert discussion from Oncology Tube, Dr. Allison Reichl (UC Irvine) breaks down the most important CLL treatment updates from ASH 2025 that will shape practice in 2026. She covers: Time-limited regimens (CLL17 trial) vs continuous BTK inhibitors Advantages and challenges of fixed-duration therapy Why unfit patients may benefit most from pushing through time-limited approaches Pirtobrutinib's strong performance in BRUIN CLL-313 and BRUIN CLL-314 Significantly lower atrial fibrillation rates compared to ibrutinib Critical sequencing considerations — when to use pirtobrutinib first-line vs as salvage Key takeaway: Pirtobrutinib shows game-changing potential with improved cardiovascular safety, but first-line use may impact future covalent BTKi options. Perfect for hematologists, oncologists, fellows, and anyone following the evolving CLL landscape. Timestamps: 00:00 – Introduction & Why Time-Limited Regimens Matter 00:36 – Challenges of Time-Limited Therapy 00:50 – Best Candidates: Unfit Patients 01:06 – CLL17 Trial: Non-Inferiority & Early Data 01:20 – MRD Benefit & Combination Therapy Questions 01:48 – VI Regimen: Practical Insights & Approval Status 02:30 – BRUIN CLL-313: Pirtobrutinib vs Chemoimmunotherapy 03:00 – Cardiovascular Safety Advantages 03:15 – Sequencing Discussion: Where Does Pirtobrutinib Fit? 03:34 – Caution on First-Line Pirtobrutinib Use 03:52 – BRUIN CLL-314: Pirtobrutinib vs Ibrutinib 04:20 – Final Takeaways & Closing Video interviews to be posted from this event at these websites... https://oncologytube.com/tag/moasc/ https://moasc.org/ About OncologyTube.com: OncologyTube.com is a free video-sharing platform dedicated to oncology professionals, offering cancer research updates through videos, audio, PowerPoint presentations, and more. Visit OncologyTube.com for a detailed web post on this and many other cancer topics and oncology insights. Follow OncologyTube: eNewsletter: https://oncologytube.com/newsletter/ Twitter: / oncologytube LinkedIn: / oncologytube-com Facebook: / oncologytube Instagram: / oncologytube YouTube: / oncologytube Connect with Us: Share your thoughts in the comments! Join the discussion.